Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
Toronto, Canada5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endometrium neoplasm, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder, rectal disorder, skin disorder, stomach disorder, uterine disorder | Recruiting | Phase 1 | 2026-10-07 | NCT07114601 | |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine neoplasm, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 / Phase 3 | 2026-09-29 | NCT06943755 | |
| A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-09-17 | NCT06827236 | |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Recruiting | Phase 3 | 2026-08-12 | NCT06801834 | |
| A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Enrolling by invitation | Phase 2 | 2026-07-28 | NCT04093570 |